Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Activation State
9%
Active Sites
9%
Antiangiogenic Therapy
9%
Bona Fide
9%
Cancer Progression
9%
Chemotherapy
9%
Clinically Significant
9%
Current Therapies
9%
Ectodomain
15%
Endogenous Inhibitor
75%
Endogenous Substances
9%
Epidermal Growth Factor Receptor Inhibitors (EGFRI)
25%
Event Sequences
9%
Expression Level
9%
Genetic Heterogeneity
9%
Glioblastoma
100%
Growth Factor Signaling
9%
Growth Inhibition
9%
Human Brain
9%
Human Glioblastoma
9%
Immunoglobulin Domain
75%
Inhibitory Activity
9%
Interaction Partner
9%
Leucine-rich Repeat Domain
75%
Local Delivery
9%
LRIG1
100%
Metabolic Heterogeneity
9%
Molecular Sequence
9%
Molecular Targets
9%
Negative Regulator
9%
Neuro-oncology
9%
Novel Therapeutics
9%
Pathway Inhibitors
9%
Primary Tumor
9%
Producer Cells
9%
Protein-protein Interaction
25%
Radiotherapy
9%
Receptor Tyrosine Kinase
86%
Receptor Tyrosine Kinase Inhibitor
25%
Signaling Pathway
9%
Soluble Form
25%
Surgical Resection
9%
Survival Benefit
9%
Therapeutic Agents
18%
Therapeutic Strategies
18%
Translational Therapy
9%
Tumor
9%
Tumor Genetics
9%
Tumor Growth
9%
Tumor Metabolism
9%
Tumor Protein p53 (TP53)
9%
Tumor Relapse
9%
Tumor Suppression
9%
Tumor Suppressor
25%
Well-defined
9%
Worse Prognosis
9%
Biochemistry, Genetics and Molecular Biology
Active Site
9%
Animal Model
9%
Downregulation
25%
Ectodomain
25%
Epidermal Growth Factor Receptor
33%
Genetic Heterogeneity
9%
Growth Factor Signaling
9%
Immunoglobulin Domain
78%
Leucine-Rich Repeat
78%
Metabolic Pathway
9%
Protein-Protein Interaction
25%
Receptor Tyrosine Kinase
92%
Signaling Mechanism
9%
Synapsin I
78%
Tumor Progression
9%
Tumor Suppressor Protein
34%
Pharmacology, Toxicology and Pharmaceutical Science
Antiangiogenic
9%
Cancer Growth
9%
Chemotherapy Regimens
9%
Epidermal Growth Factor Receptor
18%
Glioblastoma
75%
Growth Factor
9%
Immunoglobulin
75%
Leucine
75%
Malignant Neoplasm
9%
Molecular Target
9%
Neoplasm
37%
Primary Tumor
9%
Protein Tyrosine Kinase
75%
Synapsin I
75%
Tumor Growth
9%
Tumor Suppressor Protein
9%